A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 390-398

  Gomez Martin C ^a,b   Salazar, R ^c   Montagut, C ^d   Gil Martin M ^c   Nunez J A ^b   Puig, M ^e   Lin, X ^f   Khosravan, R ^f   Tursi, J M ^e   Lechuga, M J ^e   Bellmunt, J ^d  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e PFIZER INC   (United States)

^f Pf Izer Oncology Inc   (United States)

Author keywords

5 fluorouracil; Advanced gastric cancer; Cisplatin; Sunitinib

Indexed keywords

CISPLATIN; FLUOROURACIL; N DEETHYLSUNITINIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AORTA THROMBOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; PYRROLES; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 84879552381     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9830-x     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127-164
3. Ajani JA (2007) Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res 1:S16-S21
4. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, et al. (2010) Gastric cancer. J Natl Compr Canc Netw 8:378-409
5. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, the ESMO Guidelines Working Group (2010) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v50-v54
6. Van Cutsem E, Van De Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, et al. (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182-194
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
8. Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Dünschede F, et al. (2007) Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol 13:3605-3609
9. Zhang H, Wu J, Meng L, Shou CC (2002) Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8:994-998
10. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, et al. (2004) High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 10:1241-1249
11. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A (1998) Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 43:8-14
12. Wagner AD, Moehler M (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 21:381-385
13. Katano M, Nakamura M, Fujimoto K, Katano M, Nakamura M, Fujimoto K, et al. (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227:365-371
14. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, et al. (2011) Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Canc Res 13:R66
15. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605
16. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766
17. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
18. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076
19. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
20. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, et al. (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021
21. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237
22. O'Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59(Suppl 4):19-27
23. Houk BE, Bello CL (2011) Pharmacokinetics, modeling, and simulation in the development of Sunitinib Malate: a case study. Pharmacokinetics in Drug Development 261-84
24. Park SR, Lee K, Oh D, Park YI, Roh E, Khosravan R (2010) Sunitinib with cisplatin and capecitabine or oxaliplatin and capecitabine in advanced gastric cancer: a phase I, dose-finding study. Ann Oncol 21 (Abstract 815P)
25. Miyata Y, Muro K, Machida N, Hashigaki S, Li M, Lechuga MJ, et al. (2011) Phase I study of sunitinib plus S-1 and cisplatin in patients with advanced or metastatic gastric cancer. The 9th Annual Meeting of the Japanese Society of Medical Oncology, July 21-23, 2011, Yokohama, Japan (Abstract)
26. Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9:35-41
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Canc Inst 92:205-216
28. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, et al. (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70:180-187
29. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P, et al. (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92-97
30. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673